D-Dimer as a potential biomarker for disease severity in COVID-19

Özen, Mert; Yılmaz, Atakan; Çakmak, Vefa; Beyoglu, Resad; Oskay, Alten; Seyit, Murat; Şenol, Hande

doi:10.1016/j.ajem.2020.12.023

Cited by 56 publications

(51 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although the definitive diagnosis of COVID-19 disease is the RT-PCR test, many routine and non-routine biological and biochemical parameters have been examined for their diagnostic values and clinical outcomes [ [2] , [3] , [4] , [5] , [6] , [7] ]. In the Cochrane database, 21 studies that include the laboratory data of 56,585 non-COVID-19 patients and 14,126 COVID-19 patients were reviewed.…”

Section: Discussionmentioning

confidence: 99%

“…Many diagnostic and prognostic biomarkers associated with COVID-19 disease have been revealed and investigated in the literature. These include D-dimer, C-Reactive protein (CRP), neutrophil count, leukocyte count, lymphocyte ratio, neutrophil-to-lymphocyte ratio, ferritin, procalcitonin and others not routinely tested in the diagnosis and clinical prognosis of COVID-19 [ [2] , [3] , [4] , [5] , [6] , [7] ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Soluble P-selectin as a potential diagnostic and prognostic biomarker for COVID-19 disease: A case-control study

et al. 2021

View full text Add to dashboard Cite

Introduction To our knowledge, the diagnostic value of the sP-Selectin level in the diagnosis of COVID-19 disease has not yet been investigated. In this study, we aimed to assess this by evaluating the relationship between sP-Selectin level and the clinical severity of COVID-19 infections. Methods A total of 80 patients (50 with mild to moderate and 30 with severe COVID-19 pneumonia), and 60 non-symptomatic healthy volunteers participated in the study. Following serum isolation, sP-Selectin levels were assessed by Enzyme-Linked Immunosorbent Assay (ELISA) method. Results The serum sP-Selectin level was 1.7 ng/ml in the control group (1–3.78); 6.24 ng/ml (5.14–7.23) in mild-to-moderate pneumonia group; and 6.72 ng/ml (5.36–8.03) in the severe pneumonia group. Serum sP-Selectin levels in both mild-to-moderate pneumonia and severe pneumonia groups were found to be higher than the control group, with statistical significance ( p = 0.0001 and p = 0.0001, respectively). Receiver operating characteristic analysis (ROC) showed greater area under the curve (AUC) for the serum sP-Selectin levels of the COVID-19 patients (AUC = 0.913, 95% CI = 0.857–0.969; p = 0.0001). The serum sP-Selectin level was found to be 97.5% sensitive and 80% specific at 4.125 ng/ml level for diagnosis (p = 0.0001). The serum sP-Selectin level was found to be 76.9% sensitive and 51.9% specific at the level of 6.12 ng/ml ( p = 0.005) to predict the need for intensive care treatment. Conclusion This study showed that sP-Selectin can be used as a valuable biomarker in both diagnosing and predicting the need for intensive care treatment of COVID-19 infection.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Soluble P-selectin as a potential diagnostic and prognostic biomarker for COVID-19 disease: A case-control study

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Previous studies have investigated whether laboratory parameters such as monocyte/lymphocyte ratio, CRP, ferritin, lactate dehydrogenase (LDH), interleukin‐6 (IL‐6), D‐dimer, p selectin, calprotectin, and surfactant can be used as biomarkers for the clinical diagnosis and prediction of prognosis for COVID‐19. 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 The sensitivity of the markers for COVID‐19 diagnosis mentioned in these studies ranged between 66% and 97.5%. 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 …”

Section: Discussionmentioning

confidence: 94%

Annexin A1 as a potential prognostic biomarker for COVID‐19 disease: Case–control study

et al. 2021

View full text Add to dashboard Cite

Background Annexin A1 (AnxA1) is an important endogenous glucocoticoid protein that contributes to the suppression of inflammation by limiting the production of neutrophil and pro‐inflammatory cytokines. This study aims to determine the clinical predictivity value of blood AnxA1 levels in patients with mild and severe–critical pneumonia induced by COVID‐19. Methods This study employed a prospective, case–control study design and was conducted at Ankara Training and Research hospital between 10 February 2021 and 15 March 2021. A total of 74 patients (42 of whom had moderate and 32 of whom had severe/critical cases of COVID‐19 disease according to World Health Organization guidelines) and 50 nonsymptomatic healthy volunteers participated in the study. Blood samples were taken from patients at the time of hospital admission, after which serum was isolated. Following the isolation of serum, AnxA1 levels were evaluated using the enzyme‐linked immunosorbent assay method. Results The serum AnxA1 levels were measured as 25.5 (18.6‐38.6) ng/ml in the control group, 21.2 (14.7‐32) ng/ml in the moderate disease group, and 14.8 (9.7‐26.8) ng/ml in the severe/critical disease group. Serum AnxA1 levels were significantly lower in the severe/critical disease group compared with the control and moderate disease groups ( P = .01 and P = .0001, respectively). Using receiver operating characteristic analysis, a larger area under the curve (AUC) for the serum AnxA1 levels of the control group (AUC = 0.715, 95% CI = 0.626‐0.803; P = .0001) was calculated compared with the COVID‐19 patient group for the diagnosis of COVID‐19 disease. The AnxA1 level was found to be 80% sensitive and 54.1% specific at a cut‐off level of 18.5 ng/ml for the diagnosis of COVID‐19 disease. Moreover, the AnxA1 level was found to be 69.8% sensitive and 58.1% specific at a cut‐off level of 17.2 ng/ml in predicting the need for intensive care unit (ICU) treatment. Conclusion AnxA1 levels may be a beneficial biomarker in the diagnosis of COVID‐19 pneumonia and in predicting the need for ICU treatment in patients with COVID‐19 pneumonia at the time of admission to the emergency department.

show abstract

“…Также была выявлена корреляция отношения среднего объема тромбоцитов к количеству тромбоцитов с тяжестью течения COVID-19 [26]. Повышенный уровень D-димера коррелирует как с тяжестью течения, так и с исходом при COVID-19 [27,28]. Многофакторный анализ данных 245 пациентов с COVID-19 с показателем госпитальной летальности 13,47% показал, что риск внутрибольничной смерти на 8% выше при увеличении NLR на каждую единицу [29].…”

Section: результаты и обсуждениеunclassified

Biomarkers of Air-Blood Barrier Damage In COVID-19

Khadzhieva

Gracheva²,

Ершов³

et al. 2021

Obŝaâ reanimatologiâ

View full text Add to dashboard Cite

The search for sensitive and specific markers enabling timely identification of patients with a life-threatening novel coronavirus infection (COVID-19) is important for a successful treatment.The aim of the study was to examine the association of molecular biomarkers of air-blood barrier damage, surfactant proteins SP-A and SP-D and Club cell protein CC16, with the outcome of patients with COVID-19.Materials and methods. A cohort of 109 patients diagnosed with COVID-19 was retrospectively divided into two groups. Group 1 comprised survivor patients discharged from the ICU (n=90). Group 2 included the patients who did not survive (n=19). Association of disease outcome and SP-A, SP-D, and CC16 levels in blood serum, clinical, and laboratory data were examined taking into account the day of illness at the time of biomaterial collection.Results. The non-survivors had higher SP-A (from days 1 to 10 of symptoms onset) and lower CC16 (from days 11 to 20 of symptoms onset) levels vs survivors discharged from ICU. No significant differences in SP-D levels between the groups were found.Conclusion. According to the study results, the surfactant protein SP-A and Clara cell protein CC16 are associated with increased COVID-19 mortality.

show abstract

D-Dimer as a potential biomarker for disease severity in COVID-19

Cited by 56 publications

References 17 publications

Soluble P-selectin as a potential diagnostic and prognostic biomarker for COVID-19 disease: A case-control study

Soluble P-selectin as a potential diagnostic and prognostic biomarker for COVID-19 disease: A case-control study

Annexin A1 as a potential prognostic biomarker for COVID‐19 disease: Case–control study

Biomarkers of Air-Blood Barrier Damage In COVID-19

Contact Info

Product

Resources

About